ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

CORRECT: Abbott To Pay $1.6 Billion To Settle Depakote Charges

("Abbott To Pay $1.6B To Settle Depakote Charges," at 1:15 p.m. EDT, misstated the number of states involved in the settlement, in the second paragraph. The correct version follows:) DOW JONES NEWSWIRES Abbott Laboratories (ABT) agreed to pay state and federal authorities $1.6 billion to settle allegations it improperly marketed the drug Depakote for off-label uses. Under the settlement, Abbott will pay $800 million to 49 states, the District of Columbia and the federal government to resolve civil allegations it marketed Depakote, which is approved for seizures, bipolar symptoms and migraines, for other uses that aren't indicated on its label. The drug maker also agreed to pay a $700 million criminal penalty and will distribute an additional $100 million to the states to resolve consumer-protection matters. Abbott also agreed to refrain from promoting the drug for off-label uses and must take steps to ensure its sales incentives don't encourage doctors to prescribe it for other uses. The settlement came after the U.S. Justice Department began investigating whether Abbott violated civil or criminal laws by marketing Depakote as a treatment for agitation, aggression in the elderly and other uses that weren't approved by the Food and Drug Administration. Drug makers are generally barred from actively promoting off-label uses of their drugs, though doctors have the discretion to prescribe off-label. State and federal authorities have been stepping up enforcement of alleged off-label promotion in recent years. Abbott last year set aside a $1.5 billion litigation reserve to pay for the settlement. The drug maker, meanwhile, is moving forward with a plan to split into two publicly traded companies, separating its medical-products and research-based pharmaceuticals operations. The pharmaceutical wing will be responsible for the new compliance and certification requirements after the separation. The drug maker must also register and disclose clinical trials for five years and must bar sales representatives from disseminating reprints of clinical studies relating to off-label uses of Depakote. Depakote was once one of Abbott's best-selling drugs, racking up $1.6 billion in sales for 2007, before patent expirations cleared the way for cheaper generic competition. Shares were recently up 9 cents at $62.50 Monday. The stock has climbed 19% over the past year. -By Drew FitzGerald, Dow Jones Newswires; 212-416-2909; andrew.fitzgerald@dowjones.com

Stock News for Abbott Labs (ABT)
DateTimeHeadline
04/16/201413:42:24U.S. Hot Stocks: Hot Stocks to Watch
04/16/201413:41:44Abbott Labs Profit Falls 31%
04/16/201403:23:12Abbott Laboratories Statement re Proxy Materials
04/16/201403:23:12Abbott Laboratories Statement re Current Reports
04/13/201408:46:33MARKET SNAPSHOT: Google, Intel, IBM Outlooks To Trump Earnings...
02/14/201418:20:25Loeb's Third Point Took New Stakes in T-Mobile, Hertz, BlackBerry...
01/22/201413:24:11Abbott Labs Reports 44% Profit Decline -- Update
01/19/201408:17:14MARKET SNAPSHOT: 'Sloppy' Market Turns To Consumer, Tech Earnings
11/18/201308:56:09AbbVie's Treatment for Hepatitis C Shows Positive Results in...
11/15/201309:01:33HBK Investments LP 3Q 13F: Holdings As Of Sep 30
11/15/201309:01:33HBK Investments LP 3Q 13F: Holdings As Of Sep 30 -2-
11/15/201308:55:36Highbridge Capital Management 3Q 13F: Holdings As -2-
11/15/201308:55:35Highbridge Capital Management 3Q 13F: Holdings As Of Sep 30
11/15/201308:53:17D. E. Shaw & Co. LP 3Q 13F: Holdings As Of Sep 30
11/15/201308:53:17D. E. Shaw & Co. LP 3Q 13F: Holdings As Of Sep 30 -2-
11/15/201308:22:25Janus Capital Management 3Q 13F: Largest Purchases -2-
11/15/201308:22:24Janus Capital Management 3Q 13F: Holdings As Of -2-
11/15/201308:22:24Janus Capital Management 3Q 13F: Largest Purchases
11/15/201308:22:23Janus Capital Management 3Q 13F: Holdings As Of Sep 30
11/15/201307:59:25Soros Fund Management 3Q 13F: Largest Purchases

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad